Shire Sues Nostrum Pharma Over ANDA For Epilepsy Drug
The lawsuit was filed in the U.S. District Court for the District of New Jersey.
Patents on Carbatrol, an anti-convulsant that generated sales of $45 million in 2002, expire in 2011 and 2019.
Shire made total drug sales of $859 million in 2002.
The lawsuit results from an Abbreviated New Drug Application(ANDA) filed by Nostrum for a generic version of the 300 mg...
To view the full article, register now.